| Bioactivity | BBC0403 is a selective BRD2 inhibitor with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. BBC0403 exhibitS higher binding specificity for BRD2 compared to BRD3 and BRD4. BBC0403 has the potential for osteoarthritis (OA) research[1]. |
| Invitro | BBC0403（5μM、10μM 和 20μM，12 小时）可降低分解代谢因子的表达、前列腺素 E2 (PGE2) 的产生和细胞外基质 (ECM) 的降解。BBC0403 通过抑制 NF-κB 和 MAPK 信号传导来预防 OA[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BBC0403 相关抗体: |
| In Vivo | BBC0403（5-10 μg/kg；关节腔注射；每周一次；6 周）可防止小鼠 OA 软骨降解[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2644662-83-7 |
| Formula | C21H22N2O5 |
| Molar Mass | 382.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hyemi Lee, et al. BRD2-specific inhibitor, BBC0403, inhibits the progression of osteoarthritis pathogenesis in osteoarthritis-induced C57BL/6 male mice. Br J Pharmacol. 2024 Apr 10. |